Trials / Completed
CompletedNCT00454740
Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder
An Open-Label Multicenter Study to Assess the Efficacy and Safety of Daily Oral Administration of 5 and 10mg VESIcare® (Solifenacin Succinate) in Patients Who Wish to Switch From Detrol LA® (Tolterodine Tartrate Extended Release) for the Treatment of Overactive Bladder Symptoms Versus: VESIcare® Efficacy and Research Study US
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 441 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy of 5 and10mg solifenacin succinate in patients with urgency who have OAB syndrome (urgency, with or without urge incontinence, usually with frequency and nocturia) and wish to switch from tolterodine tartrate extended release to solifenacin succinate due to lack of sufficient improvement in urgency episodes
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | solifenacin succinate | Oral |
Timeline
- Start date
- 2004-06-01
- Primary completion
- 2005-08-01
- Completion
- 2005-08-01
- First posted
- 2007-04-02
- Last updated
- 2014-09-18
Locations
104 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00454740. Inclusion in this directory is not an endorsement.